David Reese Biography and Net Worth

Executive Vice President and Chief Technology Officer of Amgen

Dr. David M. Reese is Amgen's inaugural executive vice president and chief technology officer, responsible for accelerating the use of technology and artificial intelligence across all facets of the company, as well as for the company's Global Medical organization.

Dr. Reese joined Amgen in 2005 and served as executive vice president, Research and Development from 2018 to 2023. During this time, Amgen received approvals around the world for numerous innovative medicines and biosimilars, developed a robust pipeline of potential new medicines, and built a powerful discovery research capability.

Prior to joining Amgen, Dr. Reese was director of Clinical Research for the Breast Cancer International Research Group (BCIRG) and a co-founder, president and chief medical officer of Translational Oncology Research International (TORI), a not-for-profit academic clinical research organization.

Dr. Reese is a graduate of Harvard College and the University of Cincinnati College of Medicine. He completed training in Internal Medicine and Hematology/Oncology at the University of California, Los Angeles (UCLA) School of Medicine, and subsequently served on the faculty at UCLA and the University of California, San Francisco.

What is David M. Reese's net worth?: The estimated net worth of David M. Reese is at least $19.00 million as of February 19th, 2025. Dr. Reese owns 62,147 shares of Amgen stock worth more than $19,002,688 as of March 27th. This net worth estimate does not reflect any other assets that Dr. Reese may own. Additionally, Dr. Reese receives a salary of $3,400,000.00 as Executive Vice President and Chief Technology Officer at Amgen. Learn More about David M. Reese's net worth.
How old is David M. Reese?: Dr. Reese is currently 61 years old. There are 6 older executives and no younger executives at Amgen. The oldest executive at Amgen is Mr. Peter H. Griffith, Executive VP & CFO, who is 65 years old. Learn More on David M. Reese's age.
What is David M. Reese's salary?: As the Executive Vice President and Chief Technology Officer of Amgen Inc., Dr. Reese earns $3,400,000.00 per year. The highest earning executive at Amgen is Mr. Robert A. Bradway, Chairman & Chief Executive Officer, who commands a salary of $6,730,000.00 per year. Learn More on David M. Reese's salary.
How do I contact David M. Reese?: The corporate mailing address for Dr. Reese and other Amgen executives is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. Amgen can also be reached via phone at (805) 447-1000 and via email at investor.relations@amgen.com. Learn More on David M. Reese's contact information.
Has David M. Reese been buying or selling shares of Amgen?: During the past quarter, David M. Reese has sold $10,233,738.42 in Amgen stock. Most recently, David M. Reese sold 25,225 shares of the business's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $304.44, for a transaction totalling $7,679,499.00. Following the completion of the sale, the executive vice president now directly owns 36,922 shares of the company's stock, valued at $11,240,533.68. Learn More on David M. Reese's trading history.
Who are Amgen's active insiders?: Amgen's insider roster includes Robert Bradway (Chairman & Chief Executive Officer), Robert Eckert (Director), Murdo Gordon (EVP), Jonathan Graham (EVP), Peter Griffith (Exec. VP & CFO ), Nancy Grygiel (SVP), Nancy Grygiel (SVP), David Reese (Executive Vice President and Chief Technology Officer), Ronald Sugar (Director), Ronald Sugar (Director), and R Williams (Director). Learn More on Amgen's active insiders.
Are insiders buying or selling shares of Amgen?: During the last year, insiders at the medical research company sold shares 6 times. They sold a total of 71,458 shares worth more than $21,307,146.27. The most recent insider tranaction occured on February, 21st when EVP David M Reese sold 25,225 shares worth more than $7,679,499.00. Insiders at Amgen own 0.7% of the company. Learn More about insider trades at Amgen.
Information on this page was last updated on 2/21/2025.

David M. Reese Insider Trading History at Amgen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/21/2025	Sell	25,225	$304.44	$7,679,499.00	36,922
2/19/2025	Sell	8,711	$293.22	$2,554,239.42	62,147

David M. Reese Buying and Selling Activity at Amgen

Amgen Company Overview

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Today's Range

Now: $305.77

$304.29

$307.57

50 Day Range

MA: $300.39

$272.11

$327.36

2 Week Range

Now: $305.77

$253.30

$346.85

Volume

1,736,805 shs

Average Volume

2,543,311 shs

Market Capitalization

$164.26 billion

P/E Ratio

40.50

Dividend Yield

3.02%

Beta

0.53

David Reese Biography and Net Worth

What is David M. Reese's net worth?

How old is David M. Reese?

What is David M. Reese's salary?

How do I contact David M. Reese?

Has David M. Reese been buying or selling shares of Amgen?

Who are Amgen's active insiders?

Are insiders buying or selling shares of Amgen?